Related Experiment Video
Updated: May 31, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
[Functional insulin therapy courses adapted to the patient's reality]
1Service d'endocrinologie, diabétologie et métabolisme, CHUV, Lausanne. juan.ruiz@chuv.ch
Revue Medicale Suisse
|July 15, 2011
Summary
Therapeutic education, originating in diabetology, empowers patients to manage chronic conditions. The ASKAR method helps patients navigate uncertainty by focusing on Action, Situation, Knowledge, Attitude, and Resource.
Area of Science:
- Diabetology
- Patient Education
- Chronic Disease Management
Context:
- Therapeutic education originated in diabetology, where patients are key decision-makers.
- Self-monitoring and patient-led innovations, like R. K. Bernstein's basal-bolus technique, influenced early diabetes care.
- Experiential approaches have been adapted to simplify patient self-management and address uncertainty.
Purpose:
- To introduce the ASKAR method as a framework for developing patient teaching-learning sequences.
- To highlight the importance of patient experience in managing chronic diseases.
- To provide a structured approach for enhancing patient self-management skills.
Summary:
- The ASKAR method, derived from therapeutic education principles in diabetology, provides a structured approach to patient learning.
- It focuses on five key components of patient experience: Action, Situation, Knowledge, Attitude, and Resource (ASKAR).
- This method aims to improve patients' ability to manage uncertainty in chronic conditions.
Impact:
- Facilitates improved patient self-management and decision-making in chronic diseases.
- Offers a practical framework for healthcare professionals to design effective patient education programs.
- Enhances patient capacity to cope with and navigate the complexities of living with a chronic condition.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...